Literature DB >> 10071915

Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone.

S Bord1, A Horner, C A Beeton, R M Hembry, J E Compston.   

Abstract

Degradation of skeletal connective tissue is regulated, at least in part, by the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinase (TIMPs), their natural inhibitors. The balance between MMPs and TIMPs may therefore be a determinant of normal bone turnover, and imbalance could thus lead to reduced organization of bone structure. To test this hypothesis, the cellular expression of MMPs and TIMP-1 was investigated by immunohistochemistry in human neonatal rib and osteophytic and heterotopic bone; these differ in their structure, with heterotopic bone showing the least and normal rib the most organized development. In all samples, high levels of MMPs were expressed. Collagenase and stromelysin-2 were detected in chondrocytes, osteoblasts, and osteoclasts, whereas gelatinase-B was confined to osteoclasts and mononuclear cells. Matrix-associated stromelysin-1 was present in fibrous tissue and osteoid. In contrast, the expression of TIMP-1 varied markedly between the three types of bone. In heterotopic bone only occasional low level TIMP-1 expression was detected in chondrocytes and osteoblasts. Osteophytic bone showed varying levels of TIMP-1, which was matrix-bound in fibrous tissue and cell-associated in osteoblasts, chondrocytes, and occasional mononuclear cells. In both types of bone, expression of TIMP-1 by osteoclasts was absent despite large numbers of these cells. Neonatal rib bone showed consistent expression of TIMP-1, particularly in chondrocytes, osteoblasts, and lining cells. In contrast to pathological bone, many osteoclasts were TIMP-1 positive. These results suggest that, in heterotopic and osteophytic bone, the low levels of TIMP-1, and in particular its absence in osteoclasts, may partly explain the more poorly organized bone formation in these pathological bone samples. Furthermore, TIMP-1 may play a role in the regulation of bone modeling and remodeling in normal developing human bone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071915     DOI: 10.1016/s8756-3282(98)00174-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

Review 1.  Matrix remodeling during endochondral ossification.

Authors:  Nathalie Ortega; Danielle J Behonick; Zena Werb
Journal:  Trends Cell Biol       Date:  2004-02       Impact factor: 20.808

2.  Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology.

Authors:  Kathryn M Thrailkill; Cindy S Moreau; Gael Cockrell; Pippa Simpson; Rajiv Goel; Paula North; John L Fowlkes; Robert C Bunn
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

3.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

5.  A Potential Participant in Type 2 Diabetes Bone Fragility: TIMP-1 at Sites of Osteocyte Lacunar-Canalicular System.

Authors:  Qilin Pei; Jun Li; Pengfei Zhou; Jun Zhang; Peng Huang; Jingchuan Fan; Zhen Zou; Xi Li; Bin Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-23       Impact factor: 3.168

6.  Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9.

Authors:  Paola Spessotto; Francesca Maria Rossi; Massimo Degan; Raffaele Di Francia; Roberto Perris; Alfonso Colombatti; Valter Gattei
Journal:  J Cell Biol       Date:  2002-09-16       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.